TABLE 1.
Baseline subject characteristics
| Normal cognition (n = 1192) | Amnestic MCI (n = 671) | AD dementia (n = 807) | |
|---|---|---|---|
| Baseline demographics | |||
| Age (y) | 72.25 (8.28) | 74.37 (8.2) | 76.11 (7.93) |
| Female | 721 (60%) | 284 (42%) | 389 (48%) |
| Body mass index (kg/m2) | 30.72 (5.9) | 29.77 (5.88) | 28.54 (5.68) |
| Education (y) | 14.73 (3.4) | 14.26 (3.73) | 13.50 (3.99) |
| Dementia‐related measures at baseline | |||
| MMSE | 28.5 (1.72) | 26.78 (2.57) | 21.25 (5.43) |
| APOE ε4 carrier | 294 (25%) | 206 (31%) | 391 (48%) |
| AD medication use | 0 (0%) | 124 (18%) | 519 (64%) |
| Comorbidities at baseline | |||
| Hypercholesterolemia | 942 (79%) | 525 (78%) | 651 (81%) |
| Hypertension | 937 (79%) | 537 (80%) | 640 (79%) |
| Depression | 150 (13%) | 176 (26%) | 197 (24%) |
| Stroke history | 14 (1%) | 15 (2%) | 14 (2%) |
| Vitamin B12 deficiency | 68 (6%) | 47 (7%) | 81 (10%) |
| Cardiovascular disease | 120 (10%) | 74 (11%) | 100 (12%) |
| Oral hypoglycemic medications at baseline | |||
| Metformin | 824 (69%) | 448 (67%) | 473 (59%) |
| Sulfonylurea | 430 (36%) | 233 (35%) | 314 (39%) |
| Thiazolidinedione | 155 (13%) | 101 (15%) | 126 (16%) |
| DPP4 inhibitors | 55 (5%) | 41 (6%) | 58 (7%) |
| Other oral drugs | 22 (2%) | 19 (3%) | 17 (2%) |
| Injectable hypoglycemic medications at baseline | |||
| Insulin | 187 (16%) | 129 (19%) | 158 (20%) |
| Incretin mimetics | 16 (1%) | 6 (1%) | 13 (2%) |
Continuous variables and categorical variables were reported in observed/unweighted mean (SD) and counts (proportion), respectively.
Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E; DPP4, dipeptidyl peptidase‐4; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination.